Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.72 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.54 |
| ▸ | CCR4 | P51679 | 2/20 | 0.52 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL610186 | 1.00 | EIF2AK3 (0.72) | EIF2AK3AKR1C3TDP1RAB9AAKR1C1 | |
| SCHEMBL5244699 | 0.92 | EIF2AK3 (0.74) | EIF2AK3AKR1C3TDP1RAB9AAKR1C1 | |
| SCHEMBL611212 | 0.87 | TDP1 (0.67) | TDP1RAB9AKMT2ATSHRMEN1 | |
| SCHEMBL612184 | 0.87 | TDP1 (0.67) | TDP1RAB9AKMT2ATSHRMEN1 | |
| SCHEMBL610202 | 0.87 | TDP1 (0.67) | TDP1RAB9AKMT2ATSHRMEN1 | |
| SCHEMBL610201 | 0.87 | TDP1 (0.67) | TDP1RAB9AKMT2ATSHRMEN1 | |
| SCHEMBL4010826 | 0.86 | EIF2AK3 (0.73) | EIF2AK3AKR1C3RAB9AAKR1C1KMT2A | |
| SCHEMBL4010822 | 0.86 | EIF2AK3 (0.73) | EIF2AK3AKR1C3RAB9AAKR1C1KMT2A | |
| SCHEMBL4964939 | 0.85 | TDP1 (0.65) | AKR1C3TDP1RAB9AAKR1C1KMT2A | |
| SCHEMBL609607 | 0.85 | TDP1 (0.65) | AKR1C3TDP1RAB9AAKR1C1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288417-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-10-16 | — | — | US | claimed |
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-02-16 | — | — | US | claimed |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | INCYTE CORPORATION | 2006-01-05 | — | — | US | claimed |
| US-8288417-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-8071624-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | INCYTE CORPORATION | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | HSD11B1, CYP11B1, HSD3B1 | EIF2AK3 2806/4885AKR1C3 46/4885TDP1 2819/4885 |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | HSD11B1, HSD3B1, HSD11B2 | EIF2AK3 2000/4885AKR1C3 47/4885TDP1 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.